Glucowin-M 2 Forte Tablet PR is an oral antidiabetic medication formulated with Glimepiride 2mg and Metformin 1000mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and enhances peripheral insulin sensitivity, contributing to better glucose uptake by muscle tissues. The combination of these two agents provides a complementary mechanism of action, effectively lowering blood glucose levels in patients inadequately controlled by diet and exercise alone. Glucowin-M 2 Forte Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. The prolonged-release formulation ensures a steady release of active ingredients, promoting stable plasma concentrations and improved patient compliance. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, and weight gain. Regular monitoring of blood glucose and renal function is recommended during therapy. This combination therapy should be used under medical supervision to optimize therapeutic outcomes and minimize risks.